Comparative clinical trial involving 107 patients shows a complete healing rate 15.2 percentage points higher than esomeprazole.
Estimated time to complete healing reduced by approximately seven days; research paper scheduled for publication in January 2027.
Daewoong Pharmaceutical announced on the 20th that its gastroesophageal reflux disease treatment, Fexuclue, recorded a 90.2% complete healing rate at the eight-week mark in a comparative clinical trial for gastric ulcers following endoscopic submucosal dissection (ESD). The complete healing rate for the control group treated with esomeprazole was 75.0%, marking a 15.2 percentage point difference (p=0.040).
The estimated time required for complete ulcer healing was 40.31 days for the Fexuclue group, compared to 47.22 days for the esomeprazole group, a difference of approximately seven days (p=0.0449). The Fexuclue group demonstrated significantly higher ulcer reduction rates than the esomeprazole group at both the four-week and eight-week intervals.
Daewoong Pharmaceutical noted that positive results regarding healing duration were also observed in patients with ulcer areas exceeding 800㎟. The company explained that given the variations in ulcer size and healing processes among patients, these results are significant in evaluating the therapeutic efficacy of Fexuclue.
The clinical trial was conducted as a multi-center, double-blind, randomized controlled study from June 2024 to October 2025. Researchers administered either 40mg of Fexuclue or 40mg of esomeprazole once daily for eight weeks to 107 patients, evaluating ulcer reduction and complete healing rates at four and eight weeks.
ESD is a procedure used to remove tumors from the gastric mucosa via endoscopy, which leaves an artificial gastric ulcer at the resection site. Effective acid suppression therapy is critical, as incomplete healing increases the risk of complications. Daewoong Pharmaceutical stated that this study provides clinical evidence for managing post-endoscopic ulcers through a direct comparison with existing treatments.
Professor Cheol-Woong Huh of Yongin Severance Hospital, the lead researcher, stated, "In this study, 40mg of Fexuclue achieved complete healing of post-ESD gastric ulcers at a higher rate and more rapidly than esomeprazole, with a similar safety profile. Notably, the seven-day reduction in healing time confirms the rapid and potent acid-suppressive effects of P-CAB in treating iatrogenic ulcers following ESD."
Hyung-Chul Park, Head of ETC Marketing at Daewoong Pharmaceutical, added, "This study is significant in confirming that Fexuclue can heal ulcers in more patients and at a faster rate than existing PPI treatments for iatrogenic gastric ulcers following endoscopic procedures. We will continue to provide optimal treatment environments tailored to patient conditions through diverse clinical research and expanded therapeutic options."
The study results were presented as posters at domestic and international conferences, including SIDDS 2026 and UEG 2026. The paper received acceptance for publication in the international journal World Journal of Gastroenterology on September 28 and is scheduled for official publication in January 2027.







